[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438129":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":48,"centralContacts":52,"locations":58,"responsibleParty":703,"collaborators":705,"id":719,"slug":720,"hasResults":721,"nctId":722,"briefTitle":723,"officialTitle":724,"acronym":725,"eligibilityCriteria":726,"healthyVolunteers":721,"sex":727,"minAge":728,"maxAge":30,"enrollmentInfo":729,"targetDuration":30,"studyType":732,"phases":733,"briefSummary":735,"conditions":736,"keywords":30,"overallStatus":61,"whyStopped":30,"lastUpdateSubmitDate":739,"lastUpdatePostDateStruct":740,"startDateStruct":743,"completionDateStruct":745,"leadSponsor":747,"locationsCount":748},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard endocrine therapy","ACTIVE_COMPARATOR","Standard endocrine therapy will continue for up to 24 months on trial.\n\nStandard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane).",[13,14,15,16],"Drug: Tamoxifen","Drug: Letrozole","Drug: Exemestane","Drug: Anastrozole",{"label":18,"type":19,"description":20,"interventionNames":21},"Palbociclib and fulvestrant","EXPERIMENTAL","Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.\n\nPalbociclib will be given orally once a day on days 1-21 of each 28 day cycle.\n\nFulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit.",[22,23],"Drug: Palbociclib 125Mg Tab","Drug: Fulvestrant injection",[25,31,35,39,42,45],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Palbociclib 125Mg Tab","Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.",[18],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Fulvestrant injection","Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.",[18],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Tamoxifen","As per clinical guidelines",[9],{"type":26,"name":40,"description":37,"armGroupLabels":41,"otherNames":30},"Letrozole",[9],{"type":26,"name":43,"description":37,"armGroupLabels":44,"otherNames":30},"Exemestane",[9],{"type":26,"name":46,"description":37,"armGroupLabels":47,"otherNames":30},"Anastrozole",[9],[49],{"name":50,"affiliation":5,"role":51},"Nicholas Turner","PRINCIPAL_INVESTIGATOR",[53],{"name":54,"role":55,"phone":56,"phoneExt":30,"email":57},"Project Manager","CONTACT","020 7808 2887","trak-er@rmh.nhs.uk",[59,77,91,105,119,131,145,159,173,187,197,211,225,237,251,265,271,285,299,312,325,339,357,372,385,399,413,427,435,446,460,474,488,502,515,528,539,550,560,572,582,596,609,623,637,650,664,675,689],{"facility":60,"status":61,"city":62,"state":30,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Institut de Cancérologie de l'Ouest","RECRUITING","Angers","49055","France","FR",{"type":67,"coordinates":68},"Point",[69,70],-0.55202,47.47156,{"lat":70,"lon":69},[73],{"name":74,"role":55,"phone":75,"phoneExt":30,"email":76},"Anne Patsouris","0241352700","anne.patsouris@ico.unicancer.fr",{"facility":78,"status":61,"city":79,"state":30,"zip":80,"country":64,"countryCode":65,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Centre Hospitalier Annecy Genevois_Site d'Annecy","Annecy","90074",{"type":67,"coordinates":82},[83,84],6.12565,45.90878,{"lat":84,"lon":83},[87],{"name":88,"role":55,"phone":89,"phoneExt":30,"email":90},"PI, Dr Marie Vallee","0450635444","mvallee@ch-annecycygenevois.fr",{"facility":92,"status":61,"city":93,"state":30,"zip":94,"country":64,"countryCode":65,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Institut du Cancer Avignon Sainte Catherine","Avignon","84000",{"type":67,"coordinates":96},[97,98],4.80892,43.94834,{"lat":98,"lon":97},[101],{"name":102,"role":55,"phone":103,"phoneExt":30,"email":104},"Dr Julien Grenier","+33490276397","j.grenier@isc84.org",{"facility":106,"status":61,"city":107,"state":30,"zip":108,"country":64,"countryCode":65,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Centre Hospitalier Simone Veil de Blois","Blois","41016",{"type":67,"coordinates":110},[111,112],1.32912,47.59432,{"lat":112,"lon":111},[115],{"name":116,"role":55,"phone":117,"phoneExt":30,"email":118},"Oliver Arsene","+33(0)254556405","arseneo@ch-blois.fr",{"facility":120,"status":61,"city":121,"state":30,"zip":30,"country":64,"countryCode":65,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Institut Bergonié","Bordeaux",{"type":67,"coordinates":123},[124,125],-0.58046,44.84124,{"lat":125,"lon":124},[128],{"name":129,"role":55,"phone":30,"phoneExt":30,"email":130},"Monica Arnedos","m.arnedos@bordeaux.bergonie.fr",{"facility":132,"status":61,"city":133,"state":30,"zip":134,"country":64,"countryCode":65,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Centre Jean Perrin","Clermont-Ferrand","63011",{"type":67,"coordinates":136},[137,138],3.08682,45.77969,{"lat":138,"lon":137},[141],{"name":142,"role":55,"phone":143,"phoneExt":30,"email":144},"PI: Dr Xavier Durando","+334773278005","xavier.durando@clermont.unicancer.fr",{"facility":146,"status":61,"city":147,"state":30,"zip":148,"country":64,"countryCode":65,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Centre George François Leclerc","Dijon","21079",{"type":67,"coordinates":150},[151,152],5.01391,47.31344,{"lat":152,"lon":151},[155],{"name":156,"role":55,"phone":157,"phoneExt":30,"email":158},"Sylvain Ladoire","+33380737775","sladoire@cgfl.fr",{"facility":160,"status":61,"city":161,"state":30,"zip":162,"country":64,"countryCode":65,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Groupe Hospitalier Mutualiste de Grenoble","Grenoble","38000",{"type":67,"coordinates":164},[165,166],5.71479,45.17869,{"lat":166,"lon":165},[169],{"name":170,"role":55,"phone":171,"phoneExt":30,"email":172},"Elise Bonnet","+33(0)476285232","elise.bonnet@avec.fr",{"facility":174,"status":61,"city":175,"state":30,"zip":176,"country":64,"countryCode":65,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Clinique Chénieux","Limoges","87000",{"type":67,"coordinates":178},[179,180],1.24759,45.83362,{"lat":180,"lon":179},[183],{"name":184,"role":55,"phone":185,"phoneExt":30,"email":186},"Dominque Genet","+33(0)555454800","dg@imagemed-87.com",{"facility":188,"status":61,"city":175,"state":30,"zip":189,"country":64,"countryCode":65,"cosmosGeoPoint":190,"geoPoint":192,"contacts":193},"Centre Hospitalier Universitaire de Limoges","87042",{"type":67,"coordinates":191},[179,180],{"lat":180,"lon":179},[194],{"name":195,"role":55,"phone":30,"phoneExt":30,"email":196},"Elise Deluche","elise.deluche@chu-limoges.fr",{"facility":198,"status":61,"city":199,"state":30,"zip":200,"country":64,"countryCode":65,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"Centre Léon Bérard","Lyon","69373",{"type":67,"coordinates":202},[203,204],4.84789,45.74906,{"lat":204,"lon":203},[207],{"name":208,"role":55,"phone":209,"phoneExt":30,"email":210},"Dr Thomas Bachelot","+33478782654","thomas.bachelot@lyon.unicancer.fr",{"facility":212,"status":61,"city":213,"state":30,"zip":214,"country":64,"countryCode":65,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"Institut Paoli Calmettes","Marseille","13273",{"type":67,"coordinates":216},[217,218],5.38107,43.29695,{"lat":218,"lon":217},[221],{"name":222,"role":55,"phone":223,"phoneExt":30,"email":224},"Dr Renaud Sabatier","+33491223789","sabatierr@ipc.unicancer.fr",{"facility":60,"status":61,"city":226,"state":30,"zip":227,"country":64,"countryCode":65,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"Nantes","44805",{"type":67,"coordinates":229},[230,231],-1.55336,47.21725,{"lat":231,"lon":230},[234],{"name":235,"role":55,"phone":30,"phoneExt":30,"email":236},"PI: Dr Marie Robert","marie.robert@ico.unicancer.fr",{"facility":238,"status":61,"city":239,"state":30,"zip":240,"country":64,"countryCode":65,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Centre Antoine Lacassagne","Nice","06189",{"type":67,"coordinates":242},[243,244],7.26608,43.70313,{"lat":244,"lon":243},[247],{"name":248,"role":55,"phone":249,"phoneExt":30,"email":250},"PI: Dr Caroline Bailleux","+33492031114","Caroline.bailleux@nice.unicancer.fr",{"facility":252,"status":61,"city":253,"state":30,"zip":254,"country":64,"countryCode":65,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"Gustave Roussy Cancer Campus","Paris","94800",{"type":67,"coordinates":256},[257,258],2.3488,48.85341,{"lat":258,"lon":257},[261],{"name":262,"role":55,"phone":263,"phoneExt":30,"email":264},"Fabrice Andre","01.42.11.42.93","fabrice.andre@gustaveroussy.fr",{"facility":266,"status":267,"city":253,"state":30,"zip":30,"country":64,"countryCode":65,"cosmosGeoPoint":268,"geoPoint":270,"contacts":30},"Hôpital Américain de Paris","WITHDRAWN",{"type":67,"coordinates":269},[257,258],{"lat":258,"lon":257},{"facility":272,"status":61,"city":273,"state":30,"zip":274,"country":64,"countryCode":65,"cosmosGeoPoint":275,"geoPoint":279,"contacts":280},"Institut Godinot","Reims","51726",{"type":67,"coordinates":276},[277,278],4.02853,49.26526,{"lat":278,"lon":277},[281],{"name":282,"role":55,"phone":283,"phoneExt":30,"email":284},"Dr Christelle Jouannaud","+33326504383","christelle.jouannaud@reims.unicancer.fr",{"facility":286,"status":61,"city":287,"state":30,"zip":288,"country":64,"countryCode":65,"cosmosGeoPoint":289,"geoPoint":293,"contacts":294},"Centre Eugène Marquis","Rennes","25042",{"type":67,"coordinates":290},[291,292],-1.67431,48.11109,{"lat":292,"lon":291},[295],{"name":296,"role":55,"phone":297,"phoneExt":30,"email":298},"Dr Fanny Le Du","+33299252956","f.ledu@rennes.unicancer.fr",{"facility":300,"status":61,"city":301,"state":30,"zip":302,"country":64,"countryCode":65,"cosmosGeoPoint":303,"geoPoint":307,"contacts":308},"Centre Henri Becquerel","Rouen","76038",{"type":67,"coordinates":304},[305,306],1.09932,49.44313,{"lat":306,"lon":305},[309],{"name":310,"role":55,"phone":30,"phoneExt":30,"email":311},"Marianne Leheurteur","marianne.leheurteur@chb.unicancer.fr",{"facility":313,"status":61,"city":314,"state":30,"zip":315,"country":64,"countryCode":65,"cosmosGeoPoint":316,"geoPoint":320,"contacts":321},"CHU de Saint Etienne-Institut de Cancérologie","Saint-Priest-en-Jarez","42270",{"type":67,"coordinates":317},[318,319],4.37678,45.4739,{"lat":319,"lon":318},[322],{"name":323,"role":55,"phone":324,"phoneExt":30,"email":30},"Gilles Freyer","+33(0)477822937",{"facility":326,"status":61,"city":327,"state":30,"zip":328,"country":64,"countryCode":65,"cosmosGeoPoint":329,"geoPoint":333,"contacts":334},"Institut Claudius Regaud","Toulouse","31059",{"type":67,"coordinates":330},[331,332],1.44367,43.60426,{"lat":332,"lon":331},[335],{"name":336,"role":55,"phone":337,"phoneExt":30,"email":338},"Dr Florence Dolenc","+33531155122","dalenc.florence@juct-oncopole.fr",{"facility":340,"status":341,"city":342,"state":343,"zip":344,"country":345,"countryCode":346,"cosmosGeoPoint":347,"geoPoint":351,"contacts":352},"Barnet Hospital","NOT_YET_RECRUITING","London","Barnet","EN5 3DJ","United Kingdom","UK",{"type":67,"coordinates":348},[349,350],-0.12574,51.50853,{"lat":350,"lon":349},[353],{"name":354,"role":55,"phone":355,"phoneExt":30,"email":356},"PI: Neha Dr Chopra","02073528171","neha.chopra@nhs.net",{"facility":358,"status":61,"city":359,"state":360,"zip":361,"country":345,"countryCode":346,"cosmosGeoPoint":362,"geoPoint":366,"contacts":367},"Royal Cornwall Hospitals NHS Trust","Truro","Cornwall","TR1 3LJ",{"type":67,"coordinates":363},[364,365],-5.05436,50.26526,{"lat":365,"lon":364},[368],{"name":369,"role":55,"phone":370,"phoneExt":30,"email":371},"PI: Alistair Thomson","01872258303","alistairthomson1@nhs.net",{"facility":373,"status":61,"city":374,"state":30,"zip":375,"country":345,"countryCode":346,"cosmosGeoPoint":376,"geoPoint":380,"contacts":381},"University Hospitals Dorset: Royal Bournemouth Hospital","Bournemouth","BH7 7DW",{"type":67,"coordinates":377},[378,379],-1.8795,50.72048,{"lat":379,"lon":378},[382],{"name":383,"role":55,"phone":30,"phoneExt":30,"email":384},"PI: Dr Amit Chakrabarti","amit.chakrabarti@uhd.nhs.uk",{"facility":386,"status":341,"city":387,"state":30,"zip":388,"country":345,"countryCode":346,"cosmosGeoPoint":389,"geoPoint":393,"contacts":394},"Royal Sussex Hospital","Brighton","BN2 5BE",{"type":67,"coordinates":390},[391,392],-0.13947,50.82838,{"lat":392,"lon":391},[395],{"name":396,"role":55,"phone":397,"phoneExt":30,"email":398},"PI: Prof Gianfilippo Bertelli","01273696955","g.bertelli@nhs.net",{"facility":400,"status":61,"city":401,"state":30,"zip":402,"country":345,"countryCode":346,"cosmosGeoPoint":403,"geoPoint":407,"contacts":408},"Bristol Haematology and Oncology Centre","Bristol","BS2 8ED",{"type":67,"coordinates":404},[405,406],-2.59665,51.45523,{"lat":406,"lon":405},[409],{"name":410,"role":55,"phone":411,"phoneExt":30,"email":412},"PI: Jeremy Braybrooke","01173426295","Jeremy.Braybrooke@UHBW.nhs.uk",{"facility":414,"status":61,"city":415,"state":30,"zip":416,"country":345,"countryCode":346,"cosmosGeoPoint":417,"geoPoint":421,"contacts":422},"Velindre Cancer Centre","Cardiff","CF14 2TL",{"type":67,"coordinates":418},[419,420],-3.18,51.48,{"lat":420,"lon":419},[423],{"name":424,"role":55,"phone":425,"phoneExt":30,"email":426},"PI: Dr Simon Waters","02920615888","Simon.waters@wales.nhs.uk",{"facility":428,"status":61,"city":415,"state":30,"zip":416,"country":345,"countryCode":346,"cosmosGeoPoint":429,"geoPoint":431,"contacts":432},"Velindre University NHS Trust",{"type":67,"coordinates":430},[419,420],{"lat":420,"lon":419},[433],{"name":424,"role":55,"phone":434,"phoneExt":30,"email":426},"02920 615888",{"facility":436,"status":341,"city":437,"state":30,"zip":30,"country":345,"countryCode":346,"cosmosGeoPoint":438,"geoPoint":442,"contacts":443},"Darlington Memorial Hospital","Darlington",{"type":67,"coordinates":439},[440,441],-1.55039,54.52429,{"lat":441,"lon":440},[444],{"name":445,"role":55,"phone":30,"phoneExt":30,"email":30},"TBC",{"facility":447,"status":61,"city":448,"state":30,"zip":449,"country":345,"countryCode":346,"cosmosGeoPoint":450,"geoPoint":454,"contacts":455},"Western General","Edinburgh","EH4 2XU",{"type":67,"coordinates":451},[452,453],-3.19648,55.95206,{"lat":453,"lon":452},[456],{"name":457,"role":55,"phone":458,"phoneExt":30,"email":459},"PI: Dr Olga Oikonomidou","01315372193","olga.oikonomidou@nhs.scot",{"facility":461,"status":61,"city":462,"state":30,"zip":463,"country":345,"countryCode":346,"cosmosGeoPoint":464,"geoPoint":468,"contacts":469},"Royal Devon and Exeter Hospital","Exeter","EX2 5DW",{"type":67,"coordinates":465},[466,467],-3.52751,50.7236,{"lat":467,"lon":466},[470],{"name":471,"role":55,"phone":472,"phoneExt":30,"email":473},"PI: Dr Peter Stephens","01392402118","peter.stephens4@nhs.net",{"facility":475,"status":341,"city":476,"state":30,"zip":477,"country":345,"countryCode":346,"cosmosGeoPoint":478,"geoPoint":482,"contacts":483},"Beatson West of Scotland Cancer Centre","Glasgow","G12 0YN",{"type":67,"coordinates":479},[480,481],-4.25763,55.86515,{"lat":481,"lon":480},[484],{"name":485,"role":55,"phone":486,"phoneExt":30,"email":487},"PI: Prof Iain Macpherson","01413017128","Iain.macpherson@ggc.scot.nhs.net",{"facility":489,"status":61,"city":490,"state":30,"zip":491,"country":345,"countryCode":346,"cosmosGeoPoint":492,"geoPoint":496,"contacts":497},"North West Anglia NHS Foundation Trust: Hinchingbrooke Hospital","Huntingdon","PE29 6NT",{"type":67,"coordinates":493},[494,495],-0.18651,52.33049,{"lat":495,"lon":494},[498],{"name":499,"role":55,"phone":500,"phoneExt":30,"email":501},"PI: Dr Indrani Bhattacharya","01480416428","indrani.bhattacharya@nhs.net",{"facility":503,"status":341,"city":504,"state":30,"zip":505,"country":345,"countryCode":346,"cosmosGeoPoint":506,"geoPoint":510,"contacts":511},"St James's University Hospital","Leeds","LS9 7FT",{"type":67,"coordinates":507},[508,509],-1.54785,53.79648,{"lat":509,"lon":508},[512],{"name":513,"role":55,"phone":30,"phoneExt":30,"email":514},"PI: Dr David Jackson","davidpjackson@nhs.net",{"facility":516,"status":61,"city":517,"state":30,"zip":30,"country":345,"countryCode":346,"cosmosGeoPoint":518,"geoPoint":522,"contacts":523},"The Clatterbridge Cancer Centre NHS Foundation Trust","Liverpool",{"type":67,"coordinates":519},[520,521],-2.97794,53.41058,{"lat":521,"lon":520},[524],{"name":525,"role":55,"phone":526,"phoneExt":30,"email":527},"PI: Professor Carlo Palmieri","0151 556 5277","cpalmi@liverpool.ac.uk",{"facility":529,"status":61,"city":342,"state":30,"zip":530,"country":345,"countryCode":346,"cosmosGeoPoint":531,"geoPoint":533,"contacts":534},"Barts Health NHS Trust","EC1A 7BE",{"type":67,"coordinates":532},[349,350],{"lat":350,"lon":349},[535],{"name":536,"role":55,"phone":537,"phoneExt":30,"email":538},"PI: Dr Peter Hall","0787 655 4899","peter.hall12@nhs.net",{"facility":540,"status":61,"city":342,"state":30,"zip":541,"country":345,"countryCode":346,"cosmosGeoPoint":542,"geoPoint":544,"contacts":545},"Mount Vernon Hospital","HA6 2RN",{"type":67,"coordinates":543},[349,350],{"lat":350,"lon":349},[546],{"name":547,"role":55,"phone":548,"phoneExt":30,"email":549},"PI: Dr Andreas Makris","0333 332 5470","amakris@nhs.net",{"facility":551,"status":61,"city":342,"state":30,"zip":552,"country":345,"countryCode":346,"cosmosGeoPoint":553,"geoPoint":555,"contacts":556},"University College London Hospital","NW1 2BU",{"type":67,"coordinates":554},[349,350],{"lat":350,"lon":349},[557],{"name":558,"role":55,"phone":30,"phoneExt":30,"email":559},"PI: Dr Rebecca Roylance","r.roylance@ucl.ac.uk",{"facility":561,"status":61,"city":342,"state":30,"zip":562,"country":345,"countryCode":346,"cosmosGeoPoint":563,"geoPoint":565,"contacts":566},"The Royal Free Hospital","NW3 2QG",{"type":67,"coordinates":564},[349,350],{"lat":350,"lon":349},[567],{"name":568,"role":55,"phone":569,"phoneExt":570,"email":571},"PI: Dr Amna Sheri","02077940500","31918","amna.sheri@nhs.net",{"facility":573,"status":61,"city":342,"state":30,"zip":574,"country":345,"countryCode":346,"cosmosGeoPoint":575,"geoPoint":577,"contacts":578},"The Royal Marsden NHS Foundation Trust","SW3 6JJ",{"type":67,"coordinates":576},[349,350],{"lat":350,"lon":349},[579,581],{"name":54,"role":55,"phone":580,"phoneExt":30,"email":57},"02078082887",{"name":50,"role":51,"phone":30,"phoneExt":30,"email":30},{"facility":583,"status":341,"city":584,"state":30,"zip":585,"country":345,"countryCode":346,"cosmosGeoPoint":586,"geoPoint":590,"contacts":591},"Maidstone Hospital","Maidstone","ME16 9QQ",{"type":67,"coordinates":587},[588,589],0.51667,51.26667,{"lat":589,"lon":588},[592],{"name":593,"role":55,"phone":594,"phoneExt":30,"email":595},"PI: Dr Catherine Harper-Wynne","01622228631","charperwynne@nhs.net",{"facility":597,"status":61,"city":598,"state":30,"zip":599,"country":345,"countryCode":346,"cosmosGeoPoint":600,"geoPoint":604,"contacts":605},"The Christie NHS Foundation Trust","Manchester","M20 4BX",{"type":67,"coordinates":601},[602,603],-2.23743,53.48095,{"lat":603,"lon":602},[606],{"name":607,"role":55,"phone":30,"phoneExt":30,"email":608},"PI: Dr Ciara O'Brien","Ciara.obrien3@nhs.net",{"facility":610,"status":61,"city":611,"state":30,"zip":612,"country":345,"countryCode":346,"cosmosGeoPoint":613,"geoPoint":617,"contacts":618},"Nottingham University Hopsitals NHS Trust","Nottingham","NG5 1PB",{"type":67,"coordinates":614},[615,616],-1.15047,52.9536,{"lat":616,"lon":615},[619],{"name":620,"role":55,"phone":621,"phoneExt":30,"email":622},"Sarah Khan, PI","01159691169","sarah.khan@nuh.nhs.uk",{"facility":624,"status":61,"city":625,"state":30,"zip":626,"country":345,"countryCode":346,"cosmosGeoPoint":627,"geoPoint":631,"contacts":632},"Oxford Cancer & Haematology Centre, Churchill Hospital,","Oxford","OX3 7LE",{"type":67,"coordinates":628},[629,630],-1.25596,51.75222,{"lat":630,"lon":629},[633],{"name":634,"role":55,"phone":635,"phoneExt":30,"email":636},"PI: Dr Mark Tuthill","01865 72033","mark.tuthill@ouh.nhs.uk",{"facility":638,"status":61,"city":639,"state":30,"zip":640,"country":345,"countryCode":346,"cosmosGeoPoint":641,"geoPoint":645,"contacts":646},"North West Anglia NHS Foundation Trust: Peterborough Hospital","Peterborough","PE3 9GZ",{"type":67,"coordinates":642},[643,644],-0.24777,52.57364,{"lat":644,"lon":643},[647],{"name":648,"role":55,"phone":30,"phoneExt":30,"email":649},"PI: Sarah Ayers","s.ayers@nhs.net",{"facility":651,"status":61,"city":652,"state":30,"zip":653,"country":345,"countryCode":346,"cosmosGeoPoint":654,"geoPoint":658,"contacts":659},"Derriford Hospital - UHPNT","Plymouth","PL6 8DH",{"type":67,"coordinates":655},[656,657],-4.14305,50.37153,{"lat":657,"lon":656},[660],{"name":661,"role":55,"phone":662,"phoneExt":30,"email":663},"PI: Dr Sidharth Dubey","01752 431957","sdubey@nhs.net",{"facility":665,"status":61,"city":666,"state":30,"zip":667,"country":345,"countryCode":346,"cosmosGeoPoint":668,"geoPoint":672,"contacts":673},"University Hospitals Dorset: Poole Hospital","Poole","BH15 2JB",{"type":67,"coordinates":669},[670,671],-1.98458,50.71429,{"lat":671,"lon":670},[674],{"name":383,"role":55,"phone":30,"phoneExt":30,"email":384},{"facility":676,"status":61,"city":677,"state":30,"zip":678,"country":345,"countryCode":346,"cosmosGeoPoint":679,"geoPoint":683,"contacts":684},"Weston Park Hospital","Sheffield","S10 2SJ",{"type":67,"coordinates":680},[681,682],-1.4659,53.38297,{"lat":682,"lon":681},[685],{"name":686,"role":55,"phone":687,"phoneExt":30,"email":688},"Matthew Winter","01142265079","matthewwinter@nhs.net",{"facility":690,"status":61,"city":691,"state":30,"zip":692,"country":345,"countryCode":346,"cosmosGeoPoint":693,"geoPoint":697,"contacts":698},"Somerset NHS Foundation Trust","Taunton","TA1 5DA",{"type":67,"coordinates":694},[695,696],-3.10293,51.01494,{"lat":696,"lon":695},[699],{"name":700,"role":55,"phone":701,"phoneExt":30,"email":702},"PI: Dr Saiqa Spensley","01823 342417","Saiqa.Spensley@SomersetFT.nhs.uk",{"type":704,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[706,709,711,713,715,717],{"name":707,"class":708},"Pfizer","INDUSTRY",{"name":710,"class":708},"AstraZeneca",{"name":712,"class":6},"Institute of Cancer Research, United Kingdom",{"name":714,"class":6},"UNICANCER",{"name":716,"class":6},"Gustave Roussy, Cancer Campus, Grand Paris",{"name":718,"class":708},"Invitae Corporation","100438129","phase-2-a-trial-of-early-detection-of-molecular-relapse-with-circulating-tumour-dna-tracking-and-treatment-with-palbociclib-plus-fulvestrant-versus-standard-endocrine-therapy-in-patients-with-er-positive-her2-negative-breast-cancer-100438129",false,"NCT04985266","A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","TRAK-ER","Inclusion Criteria for ctDNA Surveillance:\n\n1. Written informed consent to participate in the trial and to donation of tissue and blood samples\n2. Male or female patients aged 18 years or older\n3. ECOG performance status 0, 1 or 2 (see https:\u002F\u002Fecog-acrin.org\u002Fresources\u002Fecog-performance-status)\n4. Histologically proven primary ER+ (Allred score 6\u002F8 or greater, or stain in ≥10% of cancer cells) and HER2- (immunohistochemistry 0\u002F1+ and\u002For negative by in situ hybridization) breast cancer as determined by local laboratory\n5. Patients with high risk early stage breast cancer according to at least one of the following criteria:\n\n   Primary surgery (no other treatment prior to surgery) A. Four or more involved axillary lymph nodes or positive supraclavicular lymph node at diagnosis, or\n\n   B. Tumour size \\> 5 cm, regardless of lymph node status, or\n\n   C. 1-3 involved axillary lymph nodes and at least one of the following; i) Tumour size \\> 3 cm, ii) histological grade 3 iii) high genomic risk defined as Oncotype Dx Recurrence Score \\>=26, Prosigna score \\>=60, EPclin risk score \\>=4.0, or Mammaprint high risk category, or\n\n   Neoadjuvant chemotherapy (chemotherapy prior to surgery)\n\n   D. At least one lymph node positive (micrometastasis or macrometastasis) after chemotherapy\n\n   E. Lymph node negative and tumour size \\> 3 cm after chemotherapy\n\n   Neoadjuvant endocrine therapy (endocrine based therapy prior to surgery) Use the primary surgery criteria - staging tumour size and lymph node status may be either the pathological staging after endocrine therapy or on the initial clinical staging prior to neoadjuvant therapy\n6. Available tissue from one archival tumour tissue sample (either from diagnostic biopsy, primary surgery or where available residual disease post-neoadjuvant chemotherapy)\n7. No evidence of macroscopic distant metastatic disease or incurable locally advanced disease on staging scans conducted at any time since initial diagnosis.\n8. Patients receiving standard endocrine therapy with aromatase inhibitors (letrozole, anastrazole, exemestane), tamoxifen, or combination of such for a minimum of 6 months\\* and maximum of 7 years duration with an additional three years of endocrine therapy planned. Pre- or peri-menopausal patients may also receive GnRH analogues.\n\n   \\* patients may enrol during the first 6 months of standard endocrine therapy, and wait until at least 6 months of endocrine therapy has been received prior to starting ctDNA surveillance\n9. Patients must have had surgery achieving clear margins (as per local guidelines)\n10. Female and male patients of reproductive potential must be willing to use an adequate method of contraception for the first three years of the trial, if randomised to standard endocrine therapy for the duration of trial treatment through to at least 4 weeks after the last dose of trial treatment, and if randomised to fulvestrant and palbociclib to 2 years after the last dose of fulvestrant (see section 4.6). Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.\n11. Patients willing to have frequent blood tests.\n\nInclusion Criteria for Interventional phase:\n\n1. Signed informed consent for treatment\n2. ECOG performance status 0, 1 or 2\n3. Women of childbearing potential should have a negative serum pregnancy test prior to randomisation. If randomisation occurs more than 72 hours prior to receiving the first dose of treatment the test must be repeated before treatment.\n4. Female and male patients of childbearing potential must be willing to use an adequate method of contraception (section 4.6), starting with the first dose of treatment through 4 weeks after the last dose of treatment if randomised to standard endocrine therapy and 2 years after the last dose of fulvestrant if randomised to fulvestrant and palbociclib. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient. Female patients will be deemed not of childbearing potential if they are postmenopausal or have had irreversible sterilisation\n5. Patient has adequate bone marrow and organ function as defined by the following laboratory values:\n\n   1. Absolute Neutrophil Count (ANC) ≥ 1.5 × 109\u002FL\n   2. Platelets ≥ 100 × 109\u002FL\n   3. Haemoglobin ≥ 100 g\u002FL\n   4. INR ≤1.5\n   5. Creatinine \\\u003C1.5 x ULN and creatinine clearance ≥30ml\u002Fmin\n   6. Total bilirubin \\\u003C ULN except for patients with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.\n   7. Alanine aminotransferase (ALT) \\\u003C 2.5 x ULN\n   8. Aspartate aminotransferase (AST) \\\u003C 2.5 × ULN\n6. Patients must be post-menopausal OR\n\nPre- or peri-menopausal patients or men may be enrolled if they have ovarian\u002Fgonadal suppression with licensed GnRH analogues. Patients must have commenced licensed GnRH analogues at least 2 weeks prior to Cycle 1 Day 1 and continue throughout the study if randomised to fulvestrant and palbociclib.\n\nPost-menopausal female patients, as defined by at least one of the following:\n\n* Age ≥60 years;\n* Age \\\u003C60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause, and serum estradiol and FSH levels within the institutional laboratory's reference range for post-menopausal females;\n* Documented bilateral oophorectomy;\n\nExclusion Criteria for ctDNA Surveillance:\n\n1. Any concurrent or planned treatment for the current diagnosis of breast cancer other than adjuvant endocrine therapy or a bisphosphonate.\n2. Patients with prior exposure to a CDK 4\u002F6 inhibitor as part of standard of care may enrol only after at least 12 months from completing CDK4\u002F6 therapy.\n3. Prior exposure to therapeutic dose of fulvestrant is not permitted. One subtherapeutic dose of fulvestrant is permitted.\n4. Prior diagnosis of cancer including prior diagnosis of breast cancer in the previous 5 years, other than for non-melanoma carcinoma of the skin or cervical carcinoma in situ\n5. Patients previously entered into a therapeutic trial where experimental therapy is continued post-surgery. Patients who have entered a clinical trial of a CDK4\u002F6 inhibitor in the adjuvant setting are not eligible. Patients who received a CDK4\u002F6 inhibitor only before an operation, with no post-operative adjuvant use, are eligible.\n6. Treatment with an unlicensed or investigational product within 4 weeks prior registration to trial\n7. Patient has not recovered to ≤ grade 1 (except alopecia or certain other toxicities, which in the opinion of the Investigator should not exclude the patient) from related side effects of any prior antineoplastic therapy, not including side-effects of endocrine therapy\n8. Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral medication (e.g. Crohn's disease, ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection)\n9. Patient has any other concurrent severe and\u002For uncontrolled medical condition that would, in the Investigator' opinion cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol.\n10. Clinically significant uncontrolled heart disease including any of the following:\n\n    1. History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to trial entry\n    2. Symptomatic congestive heart failure\n    3. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome.\n    4. Cardiac arrhythmia.\n11. History of pneumonitis, interstitial lung disease or pulmonary fibrosis\n12. Known history of Human Immunodeficiency Virus (HIV) (testing not required as part of study screening)\n13. Known active Hepatitis B or Hepatitis C (testing not required as part of study screening)\n14. Females who are known to be pregnant or breastfeeding\n15. History of bleeding diathesis (i.e. disseminated intravascular coagulation, clotting factor deficiency), other known abnormalities in coagulation or treatment with anticoagulants. Low molecular weight heparin (LMWH), low dose aspirin or clopidogrel are permitted.\n16. Child-Pugh class C hepatic impairment or creatinine clearance \\\u003C 30ml\u002Fmin.\n17. Patient with bilateral tumours, or unilateral multifocal cancers with multiple separate primary cancers.(Multifocal cancer that reflects a single primary cancer, in the opinion of the investigator, are eligible)\n\nExclusion Criteria for Interventional phase:\n\n1. Evidence of recurrent disease (metastatic or local, see section 6.6 for management of patients with potentially curable local recurrences) on staging scans conducted since positive ctDNA result\n2. Known hypersensitivity to the excipients of palbociclib plus fulvestrant\n3. Any anti-cancer treatment since enrolling in the TRAK-ER study other than hormonal therapy or a bisphosphonate. Prior exposure to fulvestrant is not permitted.\n4. Diagnosis of an alternative cancer since enrolment in the trial other than non-melanoma cancer of the skin or cervical carcinoma in situ\n5. Patient has had major surgery within 4 weeks prior to starting trial treatment or has not recovered from major side effects of such procedure\n6. Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with unfractionated heparin, low molecular weight heparin (LMWH), or a direct-acting oral anticoagulant (DOAC such as rivaroxaban or fondaparinux) is allowed\n7. Patient has not recovered to ≤ grade 1 (except alopecia or certain other toxicities, which in the opinion of the Investigator should not exclude the patient) from related side effects of any prior antineoplastic therapy, not including side-effects of endocrine therapy\n8. Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral medication (e.g. Crohn's disease, ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection)\n9. Patient has any other concurrent severe and\u002For uncontrolled medical condition that would, in the Investigator' opinion cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol.\n10. Clinically significant uncontrolled heart disease including any of the following:\n\n    1. History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to trial entry\n    2. Symptomatic congestive heart failure\n    3. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome.\n    4. Cardiac arrhythmia.\n11. Patient is currently receiving any of the following substances and cannot be discontinued 7 days prior to Cycle 1 Day 1:\n\n    * Medications that are strong inducers or inhibitors of CYP3A4 (section 8.5.2)\n    * Herbal preparations\u002Fmedications, dietary supplements, fruits (e.g grapefruit, pomelos, starfruit, Seville oranges) and their juice\n12. History of pneumonitis, interstitial lung disease or pulmonary fibrosis\n13. Known history of HIV (testing not required as part of study screening)\n14. Known active Hepatitis B or Hepatitis C (testing not required as part of study screening)\n15. Patient has a history of non-compliance to medical regimen\n16. History of bleeding diathesis (i.e. disseminated intravascular coagulation, clotting factor deficiency), other known abnormalities in coagulation or treatment with anticoagulants. Low molecular weight heparin (LMWH), low dose aspirin or clopidogrel are permitted.\n17. Females who are known to be pregnant or breastfeeding.","ALL","18 Years",{"count":730,"type":731},1100,"ESTIMATED","INTERVENTIONAL",[734],"PHASE2","Detection of molecular relapse with circulating tumour DNA analysis can identify which patients with ER positive breast cancer are relapsing on adjuvant endocrine therapy. This trial will aim to demonstrate that palbociclib and fulvestrant, can defer or prevent relapse in patients with ctDNA detected molecular relapse.\n\nThe TRAK-ER trial will have two phases, a ctDNA surveillance phase and a randomised therapy trial in patients with positive ctDNA.\n\nThe TRAK-ER trial will establish a ctDNA screening programme for patients with ER positive breast cancer receiving adjuvant endocrine therapy with at least a further three years of standard adjuvant endocrine therapy planned. Patients recruited into the TRAK-ER study will have high-risk clinical features to identify patients at higher risk of future relapse.\n\nctDNA assays will be used to identify which people are at very high risk of relapse (i.e. those with a positive ctDNA result), and randomise this high risk population between standard endocrine therapy versus palbociclib plus fulvestrant for up to two years.",[737,738],"ER+ Breast Cancer","HER2-negative Breast Cancer","2024-12-03",{"date":741,"type":742},"2024-12-05","ACTUAL",{"date":744,"type":742},"2022-03-30",{"date":746,"type":731},"2030-09-01",{"name":5,"class":6},49]